Roquefort Therapeutics (LON:ROQ) Insider Dr Darrin Disley Purchases 5,000,000 Shares of Stock

Roquefort Therapeutics plc (LON:ROQ) insider Dr Darrin Disley purchased 5,000,000 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The shares were purchased at an average price of GBX 170 per share, for a total transaction of £8,500,000.

Roquefort Therapeutics Trading Up 1.9%

LON ROQ opened at GBX 1.89 on Tuesday. The firm’s fifty day moving average is GBX 1.93 and its two-hundred day moving average is GBX 1.71. Roquefort Therapeutics plc has a one year low of GBX 1.08 and a one year high of GBX 5.50. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The firm has a market cap of £2.98 million, a PE ratio of -3.00 and a beta of 0.05.

Roquefort Therapeutics (LON:ROQ) last issued its quarterly earnings results on Tuesday, September 30th. The company reported GBX (0.33) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 29.57%.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.